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There was no significant change in FVC % predicted. For 
the PET scan, there was a significant fall in the standard 
uptake value (SUV) of the lung lesions. Only 3/8 patients 
remained on 80 units RCI for full 24 weeks. There was no 
significant difference in the response to therapy for those 
treated with 40- versus 80-unit RCI.
Conclusions Repository corticotropin treatment was 
prednisone-sparing and associated with significant 
improvement in DLCO, PET scan, and patient-reported 
outcome measures. A dose of 40-unit RCI twice a week 
was as effective as 80-unit RCI and was better tolerated.
Keywords Sarcoidosis · Repository corticotrophin · 
Acthar gel · PET scan · Quality of life
Introduction
Long-term treatment with anti-inflammatory drugs such 
as corticosteroids has been the mainstay of treatment of 
symptomatic pulmonary sarcoidosis [1]. However, sig-
nificant toxicity is often encountered in patients receiving 
prolonged dosage [2]. In patients who have deteriorated 
while having their prednisone withdrawn, several alterna-
tives have been investigated. These include oral cytotoxic 
agents such as methotrexate and azathioprine [3] as well as 
the biologic agent infliximab [4].
In some conditions, the use of repository corticotro-
pin (RCI) has been found to be similar or more effective 
than oral corticosteroids, with less toxicity [5–7]. A recent 
report demonstrated steroid sparing and, in some cases, 
improvement in patients with advanced sarcoidosis [8]. 
However, the dose of RCI and need for a loading dose in 
patients receiving chronic corticosteroids were unclear. 
Since toxicity may be dose-dependent and the drug is 
Abstract 
Purpose The dose of repository corticotropin (RCI) and 
need for a loading dose in sarcoidosis patients receiving 
chronic corticosteroids are unclear. We performed a single-
blind prospective study, comparing two doses of RCI in 
sarcoidosis.
Methods Chronic pulmonary sarcoidosis patients receiv-
ing prednisone therapy with deterioration by 5% in FVC in 
the previous year were studied. RCI was administered sub-
cutaneously at a loading dose of 80 units RCI for 10 days. 
Patients were randomized at day 14 to receive either 40- 
or 80-unit RCI twice a week. The dose of prednisone was 
modified by the clinician who was blinded to the patient’s 
dosage of RCI.
Results Sixteen patients completed the full 24 weeks of 
the study. At week 24, there was a decrease in the dose 
of prednisone, and improvements in DLCO, King’s Sar-
coidosis Questionnaire health status and fatigue score. 
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expensive, a reduction of dose may have significant impact 
on its use. We performed a study comparing two doses of 
RCI in advanced pulmonary sarcoidosis patient receiving 
prednisone. The primary endpoint of the study was pred-
nisone-sparing effect of RCI. We also evaluated the effect 
of RCI on pulmonary function, chest imaging, and health-
related quality of life in advanced pulmonary sarcoidosis.
Methods
This was a multi-center single-blind trial of patients with 
chronic pulmonary sarcoidosis patients. All patient met 
ATS criteria [1] for diagnosis and were on a stable dose 
of 5 mg or more prednisone for at least 3 months. Patients 
had deterioration of their pulmonary disease in the previous 
year. Patients were excluded if they had received anti-TNF 
antibody (e.g., infliximab, adalimumab) in prior 6 months 
or were receiving treatment for sarcoidosis-associated pul-
monary hypertension. The study protocol was approved by 
the local Institutional Review Board and listed in Clinical 
Trials as NCT02188017. All information was recorded 
using remote data capture (RedCAP) [9] and included some 
forms from the RedCAP shared library [10].
All eligible patients were scheduled to receive a loading 
dose of 80 Units RCI subcutaneously (SQ) once a day for 
10 days. Per protocol, patients who complained of intoler-
ance to daily treatments were instructed to stop the loading 
dose at less than 10 days. Fourteen days after starting the 
study (4 days after the last scheduled daily dose), the sub-
jects were randomized 1:1 to receive either 40- or 80-unit 
RCI twice a week for 22 more weeks. If the patient com-
plained of side effects from treatment, they were instructed 
to halve their dose of corticotrophin. The investigators were 
blinded to the dose the patient was receiving throughout the 
study.
Patients were seen at 2, 7, 11, and 24 weeks after start-
ing on RCI. At each visit, they were assessed for modifi-
cation of their prednisone dose based on previously estab-
lished algorithm [2]. If patients were felt to be improved, 
the dose of prednisone was halved. If they had been stable 
for two visits in a row (including the week 0 visit), the dose 
was halved. If the patient was clinically worse, the pred-
nisone dose was doubled. If the patient was stable for only 
one visit, there was no change in prednisone dosage. The 
dose could also be reduced for prednisone toxicity. The cli-
nician was blinded to the dose of RCI that the patient was 
receiving.
At weeks 0, 7, and 24, patients underwent history and 
physical examination, completed various questionnaires 
including the King’s Sarcoidosis Questionnaire (KSQ) 
[11], Saint George Respiratory Questionnaire (SGRQ) [12], 
and Fatigue Assessment Scale (FAS) [13], and performed 
spirometry and 6-min walk testing [14]. At week 0 and 
24, patients had their diffusion of lung of carbon monox-
ide (DLCO) measured. Predicted values for spirometry and 
DLCO were calculated [15, 16].
High-resolution computer tomography (HRCT) and [18] 
F-fluorodeoxyglucose positron emission tomography (FDG 
PET) scanning were performed initially and after 24 weeks 
of therapy. The paired HRCT scans were compared using 
a five-point Likert scale (much worse to much better) by a 
single reader (RS). The FDG PET scan was centrally read 
by one reader (RK) blinded to the treatment regimen. For 
the FDG PET scan, the highest standardized uptake value 
(SUV) for the thorax and for any other region was noted 
after the first scan. The SUVs for those same areas were 
then determined at the 24-week scan.
We prospectively examined the toxicity by regularly 
measuring hemoglobin A1C, serum glucose, blood pres-
sure, and weight. Patients also completed a steroid toxicity 
questionnaire [2].
Statistics
The study was analyzed as an intention to treat analysis, 
and at week 7, we compared those patients still receiving 
80 units RCI versus those receiving 40-unit RCI. Compari-
sons were made using Mann–Whitney U test and Wilcoxon 
test for paired samples. A p value of less than 0.05 was 
considered significant.
Results
CONSORT
Eighteen patients were enrolled into the study. Figure  1 
shows the CONSORT [17] flow sheet of outcome of all 
patients in the study. One patient withdrew before taking 
any therapy. Eight patients complained of one or more of 
the following: jitteriness (six patients), headache (three 
patients), edema (two patients), and nausea (one patient). 
One patient had the dose held because of an episode of her-
pes zoster. The treatment was reinstituted 7 days later. Over 
the course of the study, one patient withdrew during the 
initial loading period of 80 units RCI a day for 10 days. An 
additional five patients stopped the loading dose between 7 
and 9 days. These five patients remained in the study and 
began the assigned dose of either 40- or 80-unit RCI at day 
fourteen. Patients could reduce the dose by half for per-
ceived problems with drug treatment. During the 24 weeks 
of the study, seven patients reduced their dose by half (two 
of eight in the 40-unit RCI arm versus five of eight in the 
80-unit RCI arm, p > 0.05). At week 7, six patients were 
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receiving 80-unit RCI while ten patients were receiving 
40-unit RCI.
Demographics
Table  1 shows the demographic features of the sixteen 
patients who completed the 24-week study. There was no 
significant difference for the two patients who did not par-
ticipate in the study for more than 2 weeks and they were 
not further analyzed. There were no differences between 
those assigned to 40 versus 80 units of RCI in terms of age, 
race, sex, or initial pulmonary function tests. Table 2 sum-
marizes the current and past immunosuppressive therapy 
used for the two groups, with no difference between those 
assigned 40- versus 80-unit RCI. Since there was no signif-
icant difference in the features of those assigned 40 versus 
80 units of RCI, we also analyzed the effect of RCI therapy 
for the whole group.
Corticosteroid reduction
All patients were receiving prednisone at the start of the 
study. Figure  2 demonstrates the daily prednisone dose 
initially and at weeks 7 and 24 for those assigned the 40 
versus 80 units. At week 7, there was no significant differ-
ence in reduction of prednisone dosage for those receiv-
ing 80 units RCI (median 0 mg, range 0 to −20 mg) versus 
those receiving 40-unit RCI (median −2.75 mg, range 0 to 
−12.5 mg, p > 0.05). We then examined the effect of RCI 
at any dose. Compared to the initial dosage of prednisone, 
there was a significant fall in the prednisone dosage at 7 
weeks (p = 0.0156) and 24 weeks (p = 0.0078). There was 
no significant difference between the prednisone dose at 
7 versus 24 weeks. There was no significant difference 
between the 40- and 80-unit treatment groups.
Lung function
After seven weeks, there was no significant difference 
in the change in the FVC % predicted for those receiv-
ing 80-unit RCI (median 1.0%, range −9.0 to 6%) versus 
those receiving 40-unit RCI (median −3.0%, range −6.0 to 
11.0%, p > 0.05). The changes in pulmonary function test-
ing during RCI therapy at 7 and 24 weeks for all 16 patients 
are summarized in Table  3. Compared to initial values, 
there was no significant difference in the FVC or FEV-1. 
Five patients had a 5% or greater increase of the absolute 
FVC % predicted.
Fourteen patients had their DLCO measured prior to and 
after 24 weeks of therapy. There was a significant rise in the 
DLCO percent predicted after 24 weeks of therapy (Fig. 3, 
p = 0.0419). There was no significant difference in the 
6MWD at either 7 or 24 weeks. There was no significant 
Fig. 1  CONSORT flow sheet of 
patients enrolled in study. Seven 
patients reduced their treatment 
dose by half. Sixteen patients 
(eight for each treatment arm) 
completed the 24 weeks of 
study
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difference in the change in DLCO for the 40 versus 80 units 
RCI group.
Imaging
Of the 16 paired HRCT studies, one was scored as some-
what worse, nine as same, and five (31%) as somewhat bet-
ter at week 24. Table 4 summarizes the changes in pulmo-
nary function data of these patients. The change in DLCO 
percent predicted was significantly higher for the somewhat 
better group versus those with no improvement in HRCT 
(same or somewhat worse, p = 0.0237).
Fifteen patients had technically adequate PET scans 
before and after 24  weeks of RCI therapy. There was 
a significant fall in the SUV of the highest lung lesion 
from median 4.0 (range 0.8–23.5) to 2.9 (range 0.8–20.7, 
p = 0.0085). Figure 4 shows the individual values for each 
patient for those assigned to either 40 or 80 units RCI. 
There was no correlation between the PET scan results and 
Table 1  Demographics of 
patients 40-unit RCI 80-unit RCI
Number 8 8
Age, years 58 (49–68) 59 (35–60)
Male:female 3:5 4:4
African American: caucasian 4:4 3:5
FEV-1, L 1.59 (1.17–2.28) 1.78 (0.83–2.30)
FEV-1% predicted 52 (36–79)% 44.4 (36–77)%
FVC, L 2.42 (1.48–3.20) 2.51 (1.34–3.55)
FVC % predicted 68 (41–83)% 66 (48–71)%
FEV-1/FVC % 71 (49–85)% 64 (48–90)%
DLCO mL CO (STPD)/min/mmHg 13.75 (10.13–18.26) 14.50 (7.80-22.88)
DLCO % predicted 55 (23–73)% 61 (29–81)%
Organ involvement
Skin 4 2
Sinus 3 1
Eyes 0 2
Liver 0 1
Spleen 1 1
Neurologic 0 1
Extra-thoracic nodes 1 1
Parotid 1 0
Abnormal calcium metabolism 2 0
Table 2  Anti-inflammatory therapy used for sarcoidosis
a Current/past usage
Drug 40-unit RCI 80-unit RCI
Prednisone 8/0a 8/0
Methotrexate 2/4 0/2
Azathioprine 1/1 0/2
Leflunomide 1/1 0/1
Mycophenolate 0/1 0/0
Hydroxychloroquine 1/5 0/2
Infliximab 0/2 0/2
Adalimumab 0/1 0/2
Fig. 2  Daily prednisone dose initially and at weeks 7 and 24. There 
was a significant fall in the prednisone dose by week 7 (p = 0.00156) 
which persisted through week 24 (p = 0.0078). The values for those 
assigned to 40- versus 80-unit RCI are shown. There was no differ-
ence between the two groups
Lung 
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the change in DLCO, FVC percent predicted, or dose of 
prednisone during the 24 weeks of the study.
Patient‑reported outcomes
Table  5 summarizes the changes in quality of life using 
three instruments. There were significant differences in 
the KSQ for several domains, including general health 
status (GHS), general health status lung (GHS lung), and 
lung. At 7 weeks, there was no significant difference in the 
improvement in GHS between those receiving 80 units RCI 
(median 7.4, range −5.4 to 15.4) versus those receiving 40 
units RCI (median 10.8, range −7.0 to 31.6, p > 0.05). For 
all patients, there was a significant improvement (rise) in 
GHS at weeks 7 and 24 versus week 0 (Fig. 5). There was 
no significant difference in the change in GHS for those 
assigned to 40 versus 80 units RCI. Neither the SGRQ total 
or any of its three components changed significantly during 
the study. There was a significant fall (less fatigue) in the 
FAS score at week 24 (p = 0.0067). At week 7, ten patients 
had a four-point or greater drop in their FAS score. By 
week 24, eight patients still had a four-point or greater drop 
in FAS from initial values.
Adverse events
All patients completed a previously described prednisone 
toxicity questionnaire [2]. There was no significant differ-
ence in the reported toxicity including changes in moodi-
ness, appetite, or bruising. Over the 24 weeks of the study, 
there was no significant change in weight. Six of the 
patients had an elevated hemoglobin A1C at time of study 
entry. None of these six patient’s hemoglobin A1C fell into 
normal range by the end of the 24-week study. There were 
no changes in the patient’s diabetic or hypertensive medica-
tions during the course of the study. There was no differ-
ence for those in the 40- versus 80-unit RCI group.
Table 3  Pulmonary function testing before and after 7 and 24 weeks of therapy
a Median (range)
b Differs from week 0, p = 0.0419
Initial Week 7 Week 24
FVC, liters 2.42 (1.34–3.55)a 2.30 (1.08–3.87) 2.41 (1.15–3.65)
Change in FVC from Week 0 −0.08 (−0.31, +0.40) −0.05 (−0.28, +0.19)
FVC % predicted 66 (41–83) 69 (39–86) 69 (40–91)
Change in FVC % predicted from week 0, % −2.4 (−9.0, 11.0) −2.0 (−9.0,+16.0)
FEV-1, L 1.63 (0.83–2.3) 1.58 (0.74–2.69) 1.55 (0.69–2.35)
Change in FEV-1 from week 0, L −0.02 (−0.21, +0.41) −0.12 (−0.48, +0.13)
FEV-1% predicted 46 (36–79) 48 (30–94) 46 (24–95)
Change in FEV-1% predicted from week 0, % −0.5 (−10.0, +15) −3.0 (−17, +16.0)
FEV-1/FVC 70 (48–90) 68 (47–87) 62 (41–86)
Change in FEV-1/FVC from week 0, % 0.01 (−0.04, +0.07) −0.02 (−0.31, +0.04)
DLCO mm Hg 14 (7.8–22.88) 15.54 (7.7–23.38) 15.28 (5.8–24.14)
Change in DLCO from week 0 0.64 (−5.01, +6.28)
DLCO % predicted 59 (23–81) 58 (33–84) 62 (24–99)b
Change in DLCO % predicted from week 0, % 9.5 (−14.0, +27)
6MWD, m 381 (152–610) 408 (183–655) 388 (152–701)
Change in 6MWD, m 0 (−69 to 175) 0 (−137 to 297)
Fig. 3  DLCO percent predicted at weeks 0 and 24. For all patients, 
there was a significant rise in DLCO at week 24 (p = 0.0419). The 
values for those assigned to 40 versus 80 units RCI are shown. There 
was no difference between the two groups
 Lung
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Discussion
This was a prospective single-blind study comparing two 
doses of RCI in patients advanced pulmonary sarcoidosis. 
After 7 weeks, there was no significant difference between 
those receiving 80 versus 40 units of RCI twice a week. 
Over the next 17  weeks, the dose was adjusted in many 
patients. When we analyzed the effect of RCI therapy for 
all patients, regardless of dose that the patient received, 
RCI therapy was associated with a significant reduction 
in the dosage of prednisone. Despite withdrawal of pred-
nisone, patients had a significant improvement in their 
DLCO. In addition, there was a significant improvement in 
the health-related quality of life while in the study, includ-
ing lung health and reduction of fatigue.
Glucocorticoids have been the cornerstone of treatment 
of symptomatic sarcoidosis despite the limited number of 
randomized trials. The initial reports supporting use of glu-
cocorticoids included patients also treated with RCI as a 
method to stimulate glucocorticoid release [18]. For many 
years, RCI use was extremely rare in sarcoidosis due to 
the cost and presumption that glucocorticoid release was 
their only mechanism of action. Melanocortin receptors 
have been identified on other cells than the adrenal cortex, 
including inflammatory cells. Studies in infantile spastic-
ity, renal disease, and multiple sclerosis have suggested that 
the stimulation of these melanocortin receptors may be an 
important mechanism of action [19–22]. Recent experience 
with using RCI for advanced sarcoidosis has suggested 
benefit for some patients with sarcoidosis [8, 23].
The previous trials left answered some questions regard-
ing dose and frequency of administration. Long-term pred-
nisone use is associated with reduced response to ACTH 
[24]. In one study of RCI for nephrotic disease, 80-unit 
RCI twice a week was more effective but more toxic that 
40-unit RCI twice a week [22]. In the current study, five 
patients stopped the loading schedule at days seven through 
nine due to RCI toxicity. There seemed no benefit for a pro-
longed loading dose.
For patients assigned to 80-unit RCI twice a week, five 
of eight reduced their dose to 40-unit RCI twice a week, 
Table 4  HRCT score versus 
change in pulmonary function 
after 24 weeks of therapy
a Median (range)
b Significantly different from same, p = 0.0308
Somewhat worse Same Somewhat better
Number of patients 1 9 5
FVC, L −0.11 −0.04a
(−0.28, 0.19)
−0.11
(−0.19, 0.14)
FVC percent predicted, % −3 −1
(-9, 6)
−2
(-5, 16)
FEV-1, L −0.18 −0.11
(−0.48, 0.13)
−0.17
(−0.24, 0.07)
FEV-1 percent predicted, % −7 −1
(−17, 6)
−3
(−10, 16)
FEV1/FVC ratio, % −0.04 −0.01
(−0.31, 0.04)
−0.02
(−0.09, 0.031)
DLCO, mL CO (STPD)/min/mmHg 1.17 −0.22
(−5.01, 6.28)
2.905
(−1.66. 3.8)
DLCO percent predicted, %b 10 4
(−14, 26)
16.5
(11, 27)
6-min walk distance, m 0 −3.81
(−137, 297)
61.9
(0, 260)
Fig. 4  Change in SUV of highest lung lesion before and after 24 
weeks of RCI therapy. Overall, the SUV fell from median 4.0 to 2.9 
(p = 0.0085). The values for those assigned to 40 versus 80 units RCI 
are shown. There was no difference between the two groups
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while only two of eight assigned to 40-unit RCI twice a 
week reduced their dose. There was no difference in the 
response for those who were assigned to 80- or 40-unit RCI 
twice a week. At week 7, there were six patients receiv-
ing 80 units of RCI versus ten patients receiving 40 units 
of RCI. There was no significant difference between the 
two doses in the reduction of prednisone dosage, changes 
in FVC % predicted, or the quality of life of the patients. 
When we compared those initially assigned to either 80 or 
40 units of RCI, there were no differences at either 7 or 24 
weeks of the study.
The primary endpoint of this trial was the prednisone-
sparing effect of RCI. Treatment with RCI led to a signifi-
cant reduction in prednisone dose within 7 weeks and this 
persisted for the full 24 weeks of the study (Fig. 2). It has 
been previously noted that RCI was associated with reduc-
tion of prednisone in most patients who remained on drug 
for more than 3 months [8]. We were unable to demonstrate 
that the reduction in prednisone dosage during the short 
course of this study was associated with lessening of the 
toxicities associated with high-dose prednisone such as 
weight gain and diabetes. However, patients reported an 
improved quality of life while receiving RCI.
A change in FVC percent predicted is a commonly 
reported endpoint in clinical trials of sarcoidosis [25, 26]. 
A change of 5% or greater has been noted in placebo-
controlled trials of glucocorticoids [27, 28] and a subset 
of those treated with infliximab [4]. In the current study, a 
5% or greater change in FVC percent predicted at 24 weeks 
was seen in four patients. There were eight patients who 
had a ten percent or greater rise in the DLCO percent pre-
dicted at week 24. Nine of 16 (56%) of patients had either a 
significant rise in DLCO or FVC percent predicted.
This study examined two lung imaging methods. High-
resolution computer tomography (HRCT) has not been 
routinely studied in sarcoidosis treatment trials. A scor-
ing system has been used to assess lung and lymph node 
involvement, but does not provide a summation of response 
Table 5  Quality-of-life changes 
during therapy
a Median (range). GHS general health status
b Compared to week 0, p = 0.0043
c Compared to week 0, p = 0.0084
d Compared to week 0, p = 0.0034
e Compared to week 0, p = 0.0067
f Compared to week 0, p = 0.0107
g Compared to week 0, p = 0.0067
Initial Week 7 Week 24
Kings sarcoidosis questionnaire
 GHS 49.8 (15.9–70.9)a 54.3 (31.7–100)b 58.1 (23.8–100)c
 GHS Lung 51.5 (41.0–68.0) 57.8 (47.7–100)d 56.9 (44.3–100)f
 Lung 42.8 (22.3–61.0) 54.4 (33.6–100)e 49.6 (37.2–100)
Saint George respiratory questionnaire
 SGRQ activity 74.44 (35.24–92.51) 72.82 (41.63–92.51) 72.82 (47.69–92.51)
 SGRQ impacts 36.68 (13.75–70.34) 40.92 (19.34–66.55) 42.52 (17.19–66.7)
 SGRQ symptoms 53.465 (17.24–92.65) 57.98 (32.51–90.26) 46.28 (7.63–85.84)
 SGRQ total 51.49 (21.89–77.21) 54.88 (34.1–70.31) 54.13 (25.4–71.1)
Fatigue assessment scale
 FAS 28 (15–46) 26 (10–37) 22 (11–42)g
Fig. 5  King’s Sarcoidosis questionnaire (KSQ) general health at 
weeks 0, 7, and 24. Overall, there was a significant rise (better health) 
in score at week 7 (p = 0.0043) and week 24 (p = 0.0084). The values 
for those assigned to 40 versus 80 units RCI are shown. There was no 
difference between the two groups
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to treatment [29]. We used a scoring system comparing the 
HRCT before and after 24 weeks of therapy. This scoring 
system is similar to that used to score changes of routine 
chest X-ray with treatment [30–32]. Five patients had a 
somewhat better HRCT after treatment and had a signifi-
cantly greater improvement of their DLCO after treatment 
compared to those without improvement of their HRCT.
The reduction of the maximal SUV of a lung lesion has 
been reported for patients treated with infliximab [33]. In 
the current study, we also observed a significant fall in 
SUV lung and extra-thoracic lesions for most patients. This 
change in SUV occurred despite the reduction of pred-
nisone dose.
In the current study, we examined prospectively three 
patient-reported outcomes. The KSQ was developed to 
assess several components [11]. We focused on three major 
components: general health status, lung disease, and com-
bined general health status and lung. All three of these 
components improved significantly during treatment with 
RCI. The improvement averaged more than four points, 
which has been determined to be the minimally clinically 
important difference (MCID) [11]. The fatigue assessment 
scale (FAS) is a widely used instrument to assess sarcoido-
sis-associated fatigue [13]. The FAS score has been shown 
to improve with therapy with neurostimulants [34, 35] and 
physical training [36]. A change in FAS of 4 or more points 
was reported as a (MCID) [37] and was reported in half 
of the patients. There was no significant difference in the 
SGRQ during this study.
We prospectively collected adverse events associated 
with corticotopin use. In the current study, there was no 
significant change in weight during the course of the study. 
There was also no change in hemoglobin A1c levels or 
treatment for diabetes or hypertension. Eight patients com-
plained of anxiety and fluid retention on the day of drug 
administration. Many of these occurred during the daily 
loading doses. One patient withdrew from the study, the 
others stopped the loading dose, and/or reduced their dose 
by 50% and remained in the study.
There are several limitations to the current study. Many 
patients did not complete the proposed ten-day load-
ing dose due to adverse events reported by the patients. 
While discontinuation of loading dose was part of the 
protocol, the high number of patients who did not com-
plete all 10 days made it difficult to identify if there was 
any benefit from taking a loading dose. Our impression 
was that the loading dose added no benefit but enhanced 
toxicity. For the maintenance phase of the study, the pro-
tocol was designed to allow patients halve their dosage of 
RCI. By 24  weeks, only two patients were receiving 80 
units RCI. Therefore, we could not analyze the effect of 
80-unit RCI on steroid sparing or lung function at week 
24. However, we did have sufficient number of patients to 
compare 40 versus 80 units at 7 weeks. Since there was 
no significant difference at 7 weeks, we chose to analyze 
the effect of any dose of RCI on steroid sparing, lung 
function, or quality of life. For the group, there were sig-
nificant changes in some of these parameters. The study 
was designed to examine the effect of RCI on toxicity and 
prednisone sparing. Since there was no placebo group, 
we cannot be sure that reduction in prednisone dose was 
not due to effect of repeat study visits and effort to reduce 
prednisone. The reduction of prednisone dose may have 
also been due to stimulation of glucocorticoid release. 
The small number of patients limits our ability to com-
ment on the effect of RCI on pulmonary function. Also 
the study was a single-blind study. The positive results 
of this study may help in identifying which patients may 
benefit from RCI. In addition, the study may prove useful 
information for designing future trials comparing RCI to 
placebo.
In conclusion, we found that RCI was associated with 
a significant reduction of prednisone dosage. The reduc-
tion in prednisone dose may have been related to the 
glucocorticoid effect of RCI. Treatment with RCI was 
associated with a significant improvement in pulmonary 
function and chest imaging. RCI therapy was associ-
ated with improved health-related quality of life and less 
fatigue. The use of 40 units of RCI twice a week was not 
inferior to 80 units of RCI.
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